- Autores: Amaral L, Armada A, Dymek A, Handzlik J, Kiec-Kononowicz K, Martins A, Molnar J, Spengler G
- Journal: In vivo
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Activity+of+Fourteen+New+Hydantoin+Compounds+on+the+Human+ABCB1+Efflux+Pump
Multidrug resistance (MDR) is one of the major concerns in the treatment of cancer and one of the major causes of therapy failure. The overexpression of an ABC transporter, the ABCB1, is often associated with MDR in cancer. Previously it was observed that hydantoin compounds can modulate the activity of the ABCB1 pump.